RESUMO
Lists side effects of commonly used drugs which may affect nutritional status or which may be affected by food intake. Drugs are listed by general classification(in dark print), By generic name or chemical class, and by product name(AU)
Assuntos
Humanos , Interações Medicamentosas/fisiologia , Região do Caribe , Ciências da Nutrição , Países em Desenvolvimento , Dietoterapia/métodosRESUMO
Antibiotics are among the most widely used of all therapeutic agents and it is almost certainly true that they are over prescribed, both in hospitals and in the community. The evidence indicates that a good knowledge of medical microbiology among general practitioners correlates well with low prescription rates. In addition, use of the laboratory and consultation with a microbiologist has been shown to improve the rational prescribing antimicrobial chemotherapy. This short essay looks at four problems associated with antimicrobial therapy: toxicity, interactions of antibiotics with other drugs, resistance of micro-organism to antibiotics and superinfection following administration of antibiotics
Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Antibacterianos/diagnóstico , Antibacterianos/uso terapêutico , Antibacterianos/toxicidade , Resistência Microbiana a Medicamentos , Interações Medicamentosas , Superinfecção/complicações , Superinfecção/imunologia , Efeitos Colaterais e Reações Adversas Relacionados a MedicamentosAssuntos
Adulto , Idoso , Criança , Feminino , Humanos , Recém-Nascido , Masculino , Preparações Farmacêuticas/metabolismo , Meio Ambiente , Ciências da Nutrição , Consumo de Bebidas Alcoólicas , Cafeína/farmacologia , Cannabis , Anticoncepcionais Orais/farmacologia , Dieta , Interações Medicamentosas , Poluentes Ambientais , Distúrbios Nutricionais/metabolismo , TabagismoRESUMO
Intraperitoneal administration of physostigmine (0.025 to 0.18 mg/kg) to rats resulted in dignificant increases in motor activity as measured with jiggle platforms. Doses of physostigmine 0.2 mg/kg or more decreased motor activity. The physostigmine-induced hyperactivity was attenuated by atropine (5 mg/kg) given before or after physostigmine (0.05 mg/kg). On the contrary, d-amphetamine (2 mg/kg), given before or after, significantly potentiated the physostigmine-induced increase in motor activity. The relevance of the cholinergic system in mediating hyperactive behaviour in children is discussed. (AU)
Assuntos
Ratos , 21003 , Feminino , Atropina/farmacocinética , Dextroanfetamina/farmacocinética , Atividade Motora/efeitos dos fármacos , Interações Medicamentosas , Neostigmina/farmacocinética , Fisostigmina/farmacocinética , Fatores de TempoRESUMO
Rats that were treated with physostigmine (0.05 mg/kg) manifested marked hyperactive behaviour. A subsequent injection of dexamphetamine (2.0 mg/kg) did not antagonise the physostigmine-induced locomotor hyperactivity, whereas atropine (10 mg/kg) attenuated the hyperactive behaviour. Higher doses of physostigmine depressed the locomotory behaviour of rats. Carbachol and (ñ)-O-methyl-p-tyrosine did not significantly affect rats' locomotory behaviour. Implications of the results are discussed in terms of the aetiology of hyperkinesia (AU)
Assuntos
21003 , Ratos , Dextroanfetamina , Atividade Motora/efeitos dos fármacos , Fisostigmina , Carbacol , Interações Medicamentosas , MetiltirosinasRESUMO
The effects of cortisone on thyroid radio-iodine metabolism has been demonstrated in a patient. Two other patients, one euthroid and the other hyperthyroid who were receiving long term treatment with cortisone for rheumatoid arthritis, showed evidence of an enhanced response to cortisone after commencing anti-thyroid therapy with carbimazole
